Autres langues Atossa Therapeutics, Inc.

Actions

ATOS

US04962H5063

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
1,3 ^USD	-.--%		-10,96 %	+47,73 %

28/05	Atossa Therapeutics, Inc. annonce le soutien d'une étude clinique testant un nouveau modèle d'évaluation des risques de cancer du sein basé sur l'intelligence artificielle	CI
15/05	Atossa Therapeutics administre le dernier patient de l'étude de phase 2 Karisma-Endoxifen	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model	28/05
Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial	15/05
Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial	15/05
Atossa Therapeutics Files $100 Million Mixed-Shelf Offering	13/05
Atossa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Atossa Therapeutics, Inc. Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates and (Z)-Endoxifen	29/04
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer	15/04
Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	09/04
Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient	19/03
Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors	12/03
Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment	22/02
Atossa Therapeutics Rises After HC Wainwright Starts Coverage with Buy Rating	12/02
ATOSSA THERAPEUTICS, INC. : HC Wainwright revoit son opinion à la hausse	12/02
Atossa Therapeutics, Inc. Announces Full Enrollment of (Z) -Endoxifen Arm of I-Spy 2 Clinical Trial	07/02
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director	04/12
Atossa Therapeutics Says Full Enrollment Reached in Karisma-Endoxifen Trial of Breast-Cancer Drug	20/11
Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial	20/11
Atossa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors	10/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Atossa Therapeutics, Inc.

Actions

ATOS

US04962H5063

Autres langues

Filtres